<i>Hepatology</i>｜Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α

doi:10.12449/JCH2409.gwqkjpwzjj1

Volume 40 Issue 9

Sep. 2024

Turn off MathJax

Article Contents

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(9): 1766-1766

PDF( 910 KB)

Hepatology｜Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α

DOI: 10.12449/JCH2409.gwqkjpwzjj1

Published Date: 2024-09-25

Abstract

FullText(HTML)

References(0)

References

Relative Articles

[1]	Hepatology｜Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2025, 41(4): 735-735. doi: 10.12449/JCH2504.gwqkjpwzjj2
[2]	Haiqing GUO, Mingliang LI, Feng LIU, Jing ZHANG. Prevalence， influencing factors， and fibrosis risk stratification of metabolic dysfunction-associated fatty liver disease in the health check-up population in Beijing， China[J]. Journal of Clinical Hepatology, 2025, 41(4): 643-649. doi: 10.12449/JCH250408
[3]	Journal of Hepatology｜Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. Journal of Clinical Hepatology, 2024, 40(2): 257-257. doi: 10.12449/JCH2402.gwqkjpwzjj1
[4]	Hepatology International｜Gut microbiota regulates circadian oscillation in hepatic ischemia-reperfusion injury-induced cognitive impairment by interfering with hippocampal lipid metabolism in mice[J]. Journal of Clinical Hepatology, 2024, 40(1): 109-109. doi: 10.12449/JCH2401.gwqkjpwzjj1
[5]	Hepatology International｜A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study[J]. Journal of Clinical Hepatology, 2023, 39(12): 2941-2941. doi: 10.3969/j.issn.1001-5256.2023.12.gwjpwzjj2
[6]	Journal of Gastroenterology and Hepatology｜Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis[J]. Journal of Clinical Hepatology, 2023, 39(11): 2523-2523. doi: 10.3969/j.issn.1001-5256.2023.11.gwjpwzjj1
[7]	Hepatology Research｜Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1171-1171. doi: 10.3969/j.issn.1001-5256.2023.05.gwjpwzjj3
[8]	Hua ZHANG, Xuanxuan KOU, Jingxin DENG, Jiangang ZHANG. Regulatory role of hypoxia－inducible factor－1α/Yes－associated protein in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(9): 2191-2197. doi: 10.3969/j.issn.1001-5256.2023.09.024
[9]	Hepatology｜ Peroxisome proliferator - activated receptor α promotes liver enlargement and liver regeneration via the YAP-TEAD signaling pathway[J]. Journal of Clinical Hepatology, 2022, 38(2): 341-341. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj3
[10]	Hepatology｜Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(9): 2039-2039. doi: 10.3969/j.issn.1001-5256.2022.09.gwjpwzjj3
[11]	Hepatology｜Myeloid cell-specific IL-6 signal alleviates nonalcoholic fatty liver disease-related fibrosis by promoting the release of microRNA-223-enriched exosome[J]. Journal of Clinical Hepatology, 2022, 38(2): 414-414. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj6
[12]	Jiahe ZHAO, Xinyu MA, Jingya XU, Tingting DUAN, Chunlei ZHANG, Baolong LI. Research advances in related factors for autophagy in the regulation of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1713-1717. doi: 10.3969/j.issn.1001-5256.2021.07.050
[13]	Pinhua LI, Xudong LIU, Lu HUANG, Humin ZHU, Tiexiong WU, Huazhen PANG. Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2558-2561. doi: 10.3969/j.issn.1001-5256.2021.11.015
[14]	Jinjin ZHAO, Haiguang ZHANG, Feifei CUI, Lei WANG, Qingjiang MO, Luyang JIAO. Effect of hypoxia-inducible factor-1α on stemness and epirubicin sensitivity of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2021, 37(2): 354-357. doi: 10.3969/j.issn.1001-5256.2021.02.021
[15]	Liu ZhiPing, Zhao ZhiWei, Zhang JinHua. Correlation of intestinal flora with serum glucagon-like peptide-1 level in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 136-139. doi: 10.3969/j.issn.1001-5256.2020.01.030
[16]	Zhang Qing, Liu ShouSheng, Sun BaoKai, Zhang Mei, Xin YongNing. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha rs8192678 single nucleotide polymorphism with the risk of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2035-2039. doi: 10.3969/j.issn.1001-5256.2020.09.025
[17]	Zhou Dan, Zhang LiTing, Li JunFeng, Wang Shan, Xiao Ping. Mechanism of action of hypoxia-inducible factor 1α in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1604-1607. doi: 10.3969/j.issn.1001-5256.2019.07.039
[18]	Zhu JuanJuan, Cheng MingLiang, Zhao XueKe, Mu Mao. Mechanism of action of blueberry combined with probiotics in improving nonalcoholic fatty liver disease by affecting the JAK1/STAT3/BAX signaling pathway regulated by interleukin-22[J]. Journal of Clinical Hepatology, 2018, 34(9): 1936-1944. doi: 10.3969/j.issn.1001-5256.2018.09.022
[19]	Wang Li, Shi Wei, Xue Jun, Pan CuiRan, Yao Min, Yao DengFu. Regulatory effect of abnormal expression of hypoxia- inducible factor- 1α on angiogenesis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(2): 369-374. doi: 10.3969/j.issn.1001-5256.2017.02.037
[20]	Xu Xin, Jiang Man, Li JiangWen, Dong QuanYong, Lin ZhongHua, Chu LeiLei, Xin YongNing, Xuan ShiYing. Association between PPARγ gene rs3856806 polymorphism and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1088-1091. doi: 10.3969/j.issn.1001-5256.2015.07.021

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (150) PDF downloads(19)

Hepatology｜Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α

DOI: 10.12449/JCH2409.gwqkjpwzjj1

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Hepatology｜Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α

DOI: 10.12449/JCH2409.gwqkjpwzjj1

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content